<p>Bicycle Therapeutics (NASDAQ:BCYC - 获取免费报告) 预计将在 2025 年 2 月 24 日星期二市场开盘前发布其 2025 年第四季度财报。分析师预计该公司将在本季度宣布每股收益为（$1.00）。投资者可以访问该公司即将发布的 2025 年第四季度财报页面，以获取关于定于 2026 年 2 月 27 日星期五上午 2:00（东部时间）的电话会议的最新信息。</p>
<p>获取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
<h2>Bicycle Therapeutics 股票表现</h2>
<p>BCYC 的股票在星期二以$5.24 开盘。该公司的市值为 3.635 亿美元，市盈率为-1.45，贝塔值为 1.63。该公司的 50 日移动平均价格为$6.60，200 日移动平均价格为$7.10。Bicycle Therapeutics 的 52 周低点为$5.18，52 周高点为$13.11。</p>
<h2>Bicycle Therapeutics 内部活动</h2>
<p>在相关消息中，首席财务官 Alethia Young 于 1 月 5 日星期一出售了 4,334 股公司的股票。股票以平均价格$6.49 出售，总价值为$28,127.66。交易后，首席财务官直接持有 87,081 股公司股票，估值约为$565,155.69。这笔交易代表其持股减少了 4.74%。该交易已在向 SEC 提交的文件中披露，具体内容可通过此链接查看。此外，首席执行官 Kevin Lee 于 1 月 5 日星期一出售了 10,989 股公司的股票。股票以平均价格$6.46 出售，总交易额为$70,988.94。交易后，首席执行官直接持有 618,996 股公司的股票，估值约为$3,998,714.16。这代表其持股减少了 1.74%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了 38,029 股公司股票，价值为$251,966。公司内部人士持有 8.50% 的公司股票。</p>
<h2>对 Bicycle Therapeutics 的对冲基金看法</h2>
<p>一些机构投资者最近对该公司的持仓进行了调整。Brooklyn Investment Group 在第四季度购买了 Bicycle Therapeutics 的新股份，价值约为$69,000。Ausdal Financial Partners Inc.在第二季度收购了 Bicycle Therapeutics 的新股份，价值$70,000。Vontobel Holding Ltd.在第四季度购买了 Bicycle Therapeutics 的新股份，价值$71,000。Sei Investments Co.在第二季度收购了 Bicycle Therapeutics 的新股份，价值$74,000。最后，Ameriprise Financial Inc.在第二季度购买了 Bicycle Therapeutics 的新股份，价值$86,000。目前 86.15% 的股票由机构投资者持有。</p>
<h2>分析师评级变动</h2>
<p>一些股票分析师最近对 BCYC 股票发表了看法。加拿大皇家银行在 10 月 31 日星期五的研究报告中重申了 “行业表现” 评级，并将 Bicycle Therapeutics 的目标价下调至$11.00（之前为$27.00）。Weiss Ratings 在 12 月 22 日星期一的研究报告中重申了对 Bicycle Therapeutics 的 “卖出（e+）” 评级。Truist Financial 在 11 月 24 日星期一的研究报告中开始覆盖 Bicycle Therapeutics。他们设定了 “持有” 评级和$10.00 的目标价。花旗集团在 10 月 31 日星期五的研究报告中重新发布了对 Bicycle Therapeutics 的 “跑赢大盘” 评级。最后，JMP Securities 在 10 月 31 日星期五的报告中设定了 Bicycle Therapeutics 的目标价为$12.00。七位投资分析师对该股票给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Bicycle Therapeutics 目前的共识评级为 “适度买入”，共识目标价为$20.20。</p>
<p><strong>获取我们最新的 BCYC 股票报告</strong></p>
<h2>Bicycle Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Bicycle Therapeutics plc 是一家临床阶段的生物技术公司，专注于基于其专有的双环肽平台发现和开发新型肽类治疗药物。该公司的核心技术利用约束肽结构，结合了生物制剂的结合特异性和小分子的良好组织穿透特性。这种方法旨在生成具有高度选择性的药物候选者，潜在应用于包括肿瘤学、神经科学和免疫学等多个治疗领域。</p>
<p>Bicycle Therapeutics 维持着多样化的内部开发项目管道，以及与领先制药合作伙伴的合作。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Bicycle Therapeutics</li>
<li>你的银行账户不再安全</li>
<li>Nvidia 首席执行官发出大胆的特斯拉呼吁</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这只$15 的股票可能会成为 2026 年的第一只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNZQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNZQw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Bicycle Therapeutics 吗？</h2>
<p>在你考虑 Bicycle Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Bicycle Therapeutics 并不在名单上。</p>
<p>虽然 Bicycle Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

BCYC

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

BTTX

<p>Bicycle Therapeutics（纳斯达克代码：BCYC）定于 2 月 24 日发布 2025 年第四季度财报，分析师预计每股亏损 1.00 美元。该公司股票开盘价为 5.24 美元，市值为 3.635 亿美元。最近的内部交易包括首席财务官 Alethia Young 和首席执行官 Kevin Lee，他们分别以约 6.49 美元和 6.46 美元的价格出售了股票。机构投资者持有 86.15% 的股份，分析师对该股票的共识评级为 “适度买入”，目标价为 20.20 美元</p>

<p>Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter. Investors may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, February 27, 2026 at 2:00 AM ET.</p>
<div class="lb-trans"><p>Bicycle Therapeutics (NASDAQ:BCYC - 获取免费报告) 预计将在 2025 年 2 月 24 日星期二市场开盘前发布其 2025 年第四季度财报。分析师预计该公司将在本季度宣布每股收益为（$1.00）。投资者可以访问该公司即将发布的 2025 年第四季度财报页面，以获取关于定于 2026 年 2 月 27 日星期五上午 2:00（东部时间）的电话会议的最新信息。</p>
</div><p>Get <strong>Bicycle Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
</div><h2>Bicycle Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 股票表现</h2>
</div><p>Shares of BCYC opened at $5.24 on Tuesday. The company has a market capitalization of $363.50 million, a PE ratio of -1.45 and a beta of 1.63. The company's 50 day moving average price is $6.60 and its 200 day moving average price is $7.10. Bicycle Therapeutics has a 52 week low of $5.18 and a 52 week high of $13.11.</p>
<div class="lb-trans"><p>BCYC 的股票在星期二以$5.24 开盘。该公司的市值为 3.635 亿美元，市盈率为-1.45，贝塔值为 1.63。该公司的 50 日移动平均价格为$6.60，200 日移动平均价格为$7.10。Bicycle Therapeutics 的 52 周低点为$5.18，52 周高点为$13.11。</p>
</div><h2>Insider Activity at Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 内部活动</h2>
</div><p>In related news, CFO Alethia Young sold 4,334 shares of the firm's stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the transaction, the chief financial officer directly owned 87,081 shares in the company, valued at approximately $565,155.69. This trade represents a 4.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin Lee sold 10,989 shares of the business's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the transaction, the chief executive officer directly owned 618,996 shares of the company's stock, valued at approximately $3,998,714.16. This represents a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 38,029 shares of company stock valued at $251,966. Corporate insiders own 8.50% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Alethia Young 于 1 月 5 日星期一出售了 4,334 股公司的股票。股票以平均价格$6.49 出售，总价值为$28,127.66。交易后，首席财务官直接持有 87,081 股公司股票，估值约为$565,155.69。这笔交易代表其持股减少了 4.74%。该交易已在向 SEC 提交的文件中披露，具体内容可通过此链接查看。此外，首席执行官 Kevin Lee 于 1 月 5 日星期一出售了 10,989 股公司的股票。股票以平均价格$6.46 出售，总交易额为$70,988.94。交易后，首席执行官直接持有 618,996 股公司的股票，估值约为$3,998,714.16。这代表其持股减少了 1.74%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士出售了 38,029 股公司股票，价值为$251,966。公司内部人士持有 8.50% 的公司股票。</p>
</div><h2>Hedge Funds Weigh In On Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>对 Bicycle Therapeutics 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group bought a new stake in Bicycle Therapeutics during the 4th quarter valued at approximately $69,000. Ausdal Financial Partners Inc. acquired a new stake in shares of Bicycle Therapeutics in the second quarter worth $70,000. Vontobel Holding Ltd. bought a new position in Bicycle Therapeutics during the fourth quarter worth $71,000. Sei Investments Co. acquired a new position in Bicycle Therapeutics during the 2nd quarter valued at $74,000. Finally, Ameriprise Financial Inc. bought a new stake in Bicycle Therapeutics in the 2nd quarter valued at $86,000. 86.15% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近对该公司的持仓进行了调整。Brooklyn Investment Group 在第四季度购买了 Bicycle Therapeutics 的新股份，价值约为$69,000。Ausdal Financial Partners Inc.在第二季度收购了 Bicycle Therapeutics 的新股份，价值$70,000。Vontobel Holding Ltd.在第四季度购买了 Bicycle Therapeutics 的新股份，价值$71,000。Sei Investments Co.在第二季度收购了 Bicycle Therapeutics 的新股份，价值$74,000。最后，Ameriprise Financial Inc.在第二季度购买了 Bicycle Therapeutics 的新股份，价值$86,000。目前 86.15% 的股票由机构投资者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of equities analysts have recently weighed in on BCYC shares. Royal Bank Of Canada reaffirmed a &#34;sector perform&#34; rating and issued a $11.00 price target (down from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. Truist Financial initiated coverage on Bicycle Therapeutics in a research note on Monday, November 24th. They set a &#34;hold&#34; rating and a $10.00 price target for the company. Citigroup reissued an &#34;outperform&#34; rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, JMP Securities set a $12.00 price objective on Bicycle Therapeutics in a report on Friday, October 31st. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $20.20.</p>
<div class="lb-trans"><p>一些股票分析师最近对 BCYC 股票发表了看法。加拿大皇家银行在 10 月 31 日星期五的研究报告中重申了 “行业表现” 评级，并将 Bicycle Therapeutics 的目标价下调至$11.00（之前为$27.00）。Weiss Ratings 在 12 月 22 日星期一的研究报告中重申了对 Bicycle Therapeutics 的 “卖出（e+）” 评级。Truist Financial 在 11 月 24 日星期一的研究报告中开始覆盖 Bicycle Therapeutics。他们设定了 “持有” 评级和$10.00 的目标价。花旗集团在 10 月 31 日星期五的研究报告中重新发布了对 Bicycle Therapeutics 的 “跑赢大盘” 评级。最后，JMP Securities 在 10 月 31 日星期五的报告中设定了 Bicycle Therapeutics 的目标价为$12.00。七位投资分析师对该股票给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Bicycle Therapeutics 目前的共识评级为 “适度买入”，共识目标价为$20.20。</p>
</div><p><strong>Get Our Latest Stock Report on BCYC</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 BCYC 股票报告</strong></p>
</div><h2>Bicycle Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company's core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc 是一家临床阶段的生物技术公司，专注于基于其专有的双环肽平台发现和开发新型肽类治疗药物。该公司的核心技术利用约束肽结构，结合了生物制剂的结合特异性和小分子的良好组织穿透特性。这种方法旨在生成具有高度选择性的药物候选者，潜在应用于包括肿瘤学、神经科学和免疫学等多个治疗领域。</p>
</div><p>Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.</p>
<div class="lb-trans"><p>Bicycle Therapeutics 维持着多样化的内部开发项目管道，以及与领先制药合作伙伴的合作。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Bicycle Therapeutics</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Bicycle Therapeutics</li>
<li>你的银行账户不再安全</li>
<li>Nvidia 首席执行官发出大胆的特斯拉呼吁</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这只$15 的股票可能会成为 2026 年的第一只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNZQw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=BCYC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bicycle Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Bicycle Therapeutics 吗？</h2>
</div><p>Before you consider Bicycle Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bicycle Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Bicycle Therapeutics 并不在名单上。</p>
</div><p>While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bicycle Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Bicycle Therapeutics (BCYC) 预计将在周二发布季度财报